NCT07816692

Brief Summary

Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
5mo left

Started May 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress49%
May 2026Mar 2027

Study Start

First participant enrolled

May 13, 2026

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

September 8, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 14, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2027

Last Updated

September 30, 2026

Status Verified

September 1, 2026

Enrollment Period

10 months

First QC Date

September 8, 2026

Last Update Submit

September 29, 2026

Conditions

Open Angle Glaucoma (OAG)Ocular Hypertension (OHT)

Keywords

GlaucomaOcular Hypertension

Outcome Measures

Primary Outcomes (1)

  • Successful administration of iDose TR in an office-based surgical setting.

    Number of subjects that received iDose TR in an office-based surgical setting by the Investigator.

    3 months

Study Arms (1)

iDose TR

Travoprost Intracameral Implant

Combination Product: iDose TR (travoprost intracameral implant) 75 µg

Interventions

iDose TR (travoprost intracameral implant) 75 µgCOMBINATION_PRODUCT

Travoprost-releasing implant preloaded in a sterile, single-use inserter.

Also known as: iDose TR
iDose TR

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults 18 years of age or older with open-angle glaucoma or ocular hypertension

You may qualify if:

  • Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)

You may not qualify if:

  • Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye
  • Active ocular infection or inflammation
  • History of hypersensitivity to travoprost or implant components
  • Recent ocular surgery
  • Uncontrolled systemic disease
  • Any condition preventing safe implantation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Glaukos Investigative Site

Austin, Texas, 78746, United States

RECRUITING

MeSH Terms

Conditions

Glaucoma, Open-AngleOcular HypertensionGlaucoma

Condition Hierarchy (Ancestors)

Eye Diseases

Central Study Contacts

Study Director

CONTACT

949-739-8749ClinicalResearch@glaukos.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 8, 2026

First Posted

September 14, 2026

Study Start

May 13, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 1, 2027

Last Updated

September 30, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

Locations

US(1)